IPO5 Knouckout Jurkat Polyclonal Cells are a CRISPR/Cas9-edited pooled population of Jurkat T lymphocytes carrying heterogeneous disruptions in the IPO5 gene. This polyclonal format allows population-averaged assessment of loss-of-function phenotypes, minimizing clonal selection bias. The cells are a convenient tool for functional genomic screens, drug sensitivity studies, and mechanistic dissection of nuclear transport pathways in a T-cell context.
The Jurkat host cell line is an immortalized human T lymphocyte from a patient with acute T-cell leukemia. It is extensively used for T-cell receptor signaling, apoptosis, and cytokine studies, displaying constitutive NF-??B activity and IL-2 inducibility. This leukemic context provides a relevant system for exploring nucleocytoplasmic transport defects in malignancy and T-cell biology.
IPO5 encodes Importin-5, a Ran-dependent karyopherin-?? receptor that transports cargo through the nuclear pore complex. Key cargoes include ribosomal proteins (RPLs) and histone H1, linking transport to ribosome biogenesis and chromatin. Upstream regulators include MYC, E2F, PI3K/AKT, and MAPK pathways. Importin-5 also imports HIV-1 integrase, influenza nucleoprotein, STAT3, and p53, interacting with Ran, NUP62, NUP153, and KPNA2. By mediating this broad cargo spectrum, IPO5 integrates proliferation, stress, and viral replication signals.
CRISPR-mediated IPO5 disruption in Jurkat cells impairs nuclear import of its cargoes, likely attenuating ribosomal traffic and proliferation. The knockout may sensitize cells to apoptosis or modulate TCR signaling. Additionally, reduced HIV-1 preintegration complex import can inhibit viral replication, making these cells a model for host-pathogen studies and compensatory transport analysis.
These cells enable nuclear import assays, flow cytometry of T-cell activation, HIV-1 p24 ELISA, co-immunoprecipitation, and transcriptomic profiling. They provide a platform for importin inhibitor screening and rescue experiments. For technical inquiries, contact Ascent Research.
